REG - Roquefort Theraptcs. - Determination of Record Date and Entitlement

Roquefort TherapeuticsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251201:nRSA5583Ja&default-theme=true

RNS Number : 5583J  Roquefort Therapeutics PLC  01 December 2025

1 December 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Determination of Record Date and Entitlement

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company,
announces that, following the announcement on 3 November 2025 regarding the
proposed issue of new unlisted redeemable non-voting shares ("Unlisted RNV
Shares"), the Company confirms that the record date for determining
entitlement to the Unlisted RNV Shares has now passed.

 

Holders of ordinary shares and convertible loan notes who were on the
Company's registers as at close of business on 30 November 2025 (the "Record
Date") will be entitled to receive Unlisted RNV Shares.

 

The Unlisted RNV Shares will carry the right to all future commercial benefits
arising from the Company's Midkine Investments portfolio, with the ultimate
intention of facilitating an in-specie distribution of the Midkine Investments
shares to the holders of Unlisted RNV Shares when the Company's balance sheet
permits such a distribution in accordance with the Companies Act 2006.

 

Full details of the entitlement ratio, the exact number of Unlisted RNV Shares
to be issued, the crediting process and the anticipated timetable will be set
out in a further announcement to be made in due course.

 

Regulatory Information

This Announcement contains inside information for the purposes of the UK
version of the market abuse regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR").

 

ENDS

 
Enquiries:
 Roquefort Therapeutics plc                               +44 (0)20 3918 8633
 Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
 SP Angel Corporate Finance LLP (Broker to the Company)   +44 (0)20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Shard Capital Partners LLP (Broker to the Company)       +44 (0)20 4530 6926

 Damon Heath
 Burson Buchanan (Public Relations)                       +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is focused on completing the proposed
transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which
will result in the Company acquiring the exclusive licence rights to AO-252, a
novel first-in-class, first-in-human new drug alternative targeting the TACC3
protein for the treatment of certain cancers, initially announced by the
Company on 8 September 2025.

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFSRLTLIVIE



            Copyright 2019 Regulatory News Service, all rights reserved